Currently, surgery after neoadjuvant chemoradiotherapy is the standard treatment for patients
with locally advanced esophageal cancer, but the recurrence rate is high and the 5-year
survival rate is low. Immunotherapy shows a potential treatment for esophageal cancer.
Immunocheckpoint (PD-1/PD-L1) inhibitors can activate tumor immunity. The guidelines have
recommended it as a sencond-line therapy. However, there is still lack of the evidence for
its efficacy as a neoadjuvant therapy. This study is to conduct a randomized controlled, open
label, phase II clinical trial to evaluate the efficacy and safety of neoadjuvant
immnotherapy combined with neoadjuvant chemotherapy for locally advanced esophageal squamous
cell carcinoma (ESCC) patient with PD-L1 (CPS>=10%) positive.